Pharmaceutical company PKC Pharma has published list of companies known to have sold the incorrect isomer of the kinase inhibitor bosutinib, which researchers are studying as a potential chemotherapeutic agent. As The Scientist reported earlier this month (see Mismarketed Chemical Causes Concern), inconsistent NMR spectra alerted the biochemical community that an incorrect isomer of bosutinib had entered the marketplace. PKC Pharma, after being notified that its own bosutinib was actually the incorrect isomer, began purchasing and testing bosutinib from different vendors to learn how many may have unwittingly sold an incorrect form of bosutinib. This week (May 23), the company listed 17 vendors on its website that it says sold the incorrect isomer, verified by several tests including proton NMR.

PKC Pharma, which had distributed bostunib bought from other suppliers, will seek refunds from companies that supplied the incorrect isomer, said President Paul Driedger, and...

Interested in reading more?

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?